December 12th, 2025 10:00 EST
https://www.bocsci.com/delivery-nanocarriers-to-desirable-vascular-destinations-fortuitous-tropism-vs-cognizant-targeting.html
Free registration

In this session, Dr. Vladimir Muzykantov will present an in-depth analysis of the current advances and challenges in drug targeting, biomaterials, nanomedicine, drug delivery systems (DDS), intracellular delivery, and biotherapeutics (Bios).

HIGHLIGHTS

Biotherapeutics (Bios) as a new pharmacological class: Discussion of their catalytic precision, biological potency, and delivery challenges within systemic circulation.

Delivery challenges and bottlenecks: Exploration of nanoscale targeting requirements, intracellular addressing (cytosol vs nucleus), and barriers to effective biodistribution and clearance.

Cognizant vs. Fortuitous Targeting Approaches: Comparison of rational ligand-based targeting versus chance discoveries ("fortuitous homing"), including advantages, limitations, and potential synergies.

Mechanistic understanding through DDS design: How tracing, modeling, and controlled modification of nanocarriers advance rational design for vascular delivery.

Re-engineering Fortuitous Nanocarriers: Strategies to transform serendipitous findings into predictable and tunable delivery platforms through modulation of carrier configuration, size, shape, and biological context.

Translational impact – Vascular Nanomedicine: Case studies where endothelial-targeted antioxidants, antithrombotics, and anti-inflammatory agents outperform untargeted drugs in animal models of lung injury, ischemia-reperfusion, and sepsis.